https://doi.org/10.55788/ba660775
The CCG is a global collaboration to uncover the genetic basis of cluster headache and other rare headache disorders, in which 15 medical institutions currently cooperate (https://www.clusterheadachegenetics.org/). Dr Caroline Ran (Karolinska Institute, Sweden) and colleagues performed a meta-analysis including 4,043 patients with clinically diagnosed cluster headache and 21,729 controls from 9 European countries.
The polygenic basis of cluster headache was confirmed, with a single nucleotide polymorphism (SNP)-based heritability of 14.5%. The analysis identified 7 genome-wide loci for cluster headache. Four of these had been previously identified on chromosomes 1, 2, and 6: DUSP10, rs17011182 (OR 1.38); MERTK, rs13399108 (OR 1.41); FTCDNL1, rs6714578 (OR 1.53); and FHL5, rs9486725 (OR 1.29). Three were novel, on chromosomes 7, 10, and 12: WNT2, rs2402176 (OR 1.20); PLCE1, rs57866767 (OR 1.18); and LRP1, rs11172113 (OR 1.18). There was an overlap with known migraine loci.
Downstream analysis revealed a significant genetic correlation of cluster headache with 84 traits. Among these were risk-taking behaviour, ADHD, depression, and musculoskeletal pain. However, the most significant correlation was with cigarettes smoked per day; 10 of the 84 identified traits were related to smoking. To further dissect this effect, Mendelian randomisation analysis was performed using 40 SNPs previously associated with smoking. Inverse variant-weighted analysis indicated a causal effect of cigarette smoking intensity on cluster headache (P<0.0001). This observation, the authors concluded, may have clinical implications.
- Winsvold BS, et al. Cluster headache genome-wide association study identifies seven loci and implicates smoking as causal risk factor. A5, EHC 2022, 07–10 December, Vienna, Austria.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Towards precision medicine: salivary CGRP and erenumab response Next Article
IHS President: “It is time for operationalisation of ICHD” »
« Towards precision medicine: salivary CGRP and erenumab response Next Article
IHS President: “It is time for operationalisation of ICHD” »
Table of Contents: EHC 2022
Featured articles
EHF consensus on effective migraine treatment and triptan failure
IHS President: “It is time for operationalisation of ICHD”
Headache Prophylaxis
Intervention
EHF consensus on effective migraine treatment and triptan failure
Sustained long-term effect of occipital nerve stimulation in MICCH
Onabotulinumtoxin A effective in older patients with chronic migraine
What to do when conventional treatment of headache fails in children
Predicting response to medical and surgical treatment of trigeminal neuralgia
Breakthroughs in Understanding Headache
IHS President: “It is time for operationalisation of ICHD”
GWAS identifies 7 loci for cluster headache
Towards precision medicine: salivary CGRP and erenumab response
Persistent headache after stroke: not rare and often overlooked
Additional effects of gepants on top of erenumab
Headache Prevention
Idiopathic intracranial hypertension: key factors influencing visual outcomes
Patients with migraines smoke less, drink less, and use fewer illicit drugs than general population
Related Articles
July 30, 2019
Fremanezumab efficacy and safety maintained over 1 year
August 18, 2021
Pregnant migraine patients at higher risk of complications
June 2, 2022
Migraine may be an important obstetric risk factor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com